Background {#s1}
==========

Neuroblastoma (NB) is the most frequent, solid malignancy in childhood outside the central nervous system. More than 90% of children with NB are diagnosed until the age of 6 years. The presence of *MYCN* amplification and/or metastatic disease (stage M) are considered high-risk features in patients with NB. In this group, 5-year event-free survival is still below 50% despite multimodal therapy including chemotherapy, surgery, radiotherapy, high-dose chemotherapy with autologous stem cell rescue and maintenance therapy.[@R1] Therefore, identifying new treatment strategies for these patients is of major importance.

Disialoganglioside (GD~2~) is a glycolipid of the cell membrane. It is found on all NB cells with limited expression on normal tissue,[@R2] and is an established target for immunotherapy in patients with NB.

In the ANBL 0032 study of the Children's Oncology Group, administration of the human/mouse chimeric anti-GD~2~ antibody ch14.18 produced in SP2/0 cells (dinutuximab) in combination with granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin 2 (IL-2) resulted in an improved survival of patients with high-risk NB.[@R3] Similarly, two trials of the International Society of Paediatric Oncology European Neuroblastoma (SIOPEN) group showed a benefit for patients with high-risk NB treated with dinutuximab beta (DB). DB is different from dinutuximab as this variant was produced in Chinese hamster ovary cells. This introduced variations in the glycosylation pattern followed by enhanced antibody effector functions.[@R4] Improved survival was found in first-line maintenance treatment (HR-NBL-SIOPEN/1 study[@R5]) as well as in patients with relapsed and refractory NB.[@R6]

DB was approved by the European Medicines Agency in 2017 for the treatment of patients with relapsed or refractory NB. The primary mechanism of action of DB is the induction of an antibody-dependent cell-mediated cytotoxicity, mediated mainly by natural killer (NK) cells.[@R7] The contribution of macrophages, monocytes and neutrophils to the clinical effect of DB is not clear to date. The cytotoxic response of effector cells is activated by immunoglobulin receptors (FCGR) on the cell surface on recognition of DB bound to NB cells.[@R8] FCGR3A is expressed on the surface of NK cells and FCGR2A is expressed on macrophages, monocytes and neutrophils. Frequent clinical adverse effects of DB include the induction of neuropathic pain and capillary leak syndrome.[@R6]

Whereas passive immune therapy with DB has evolved as a treatment option for pediatric patients with high-risk NB, active immune therapy approaches such as checkpoint inhibitors have been developed and approved for adult patients with cancer.[@R9] The first checkpoint inhibitor ipilimumab targeting the CTLA-4 molecule was approved for patients with melanoma in 2011.[@R10] Programmed cell death protein 1 (PD-1) is another checkpoint mainly expressed on activated T cells and NK cells.[@R11] PD-1 inhibits immune responses after binding to its programmed death ligands, PD-L1 and PD-L2. PD-L1 is expressed on hematopoietic and epithelial cells, PD-L2 on macrophages and dendritic cells. An upregulation of both ligands can be observed in malignant diseases, PD-L1 predominantly in solid tumors, PD-L2 in B cell lymphoma.[@R9] In NB, PD-L1 expression is low. However, a constitutive and inducible PD-L1 expression was shown in several cell lines.[@R12]

Nivolumab is a monoclonal antibody that inhibits the PD-1/PD-L1 checkpoint by specifically binding to PD-1 and is approved for the treatment of patients with malignant diseases including melanoma, non-small cell lung cancer and Hodgkin lymphoma.

In a preclinical NB model it was demonstrated that low PD-L1 expression was upregulated by the treatment with DB, and a combined treatment with a murine anti-PD-1 antibody and DB induced a synergistic anti-NB immune response in a syngeneic mouse model.[@R14] Therefore, this combination might be a reasonable approach for patients with NB. As both DB and nivolumab lead to immune system activation, autoimmune phenomena are possible adverse effects particularly to be considered with this approach. Here, we report the results of combined treatment with nivolumab and DB in two patients with relapsed/refractory NB.

Case presentations {#s2}
==================

Patient 1 {#s2-1}
---------

In August 2013, a 4-year-old girl was diagnosed with *MYCN*-amplified, metastatic retroperitoneal NB stage M according to the International Neuroblastoma Staging System (INSS). As the patient's NB was ^123^I-metaiodobenzylguanidine (mIBG)-negative, ^18^F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (^18^F-FDG PET/CT) was used for tumor assessments. The girl received multimodal high-intensity first-line and relapse treatment ([table 1](#T1){ref-type="table"}). She was admitted to the University Children's Hospital Greifswald in December 2017 with active disease. From December 2017 until September 2018, she was first treated with a combination of DB and chemotherapy elements from the NB protocol NB2004. As the girl developed prolonged periods of granulocytopenia and recurrent urinary tract infections, we decided to continue her treatment with DB and irinotecan/temozolomide. After an initial response she developed progressive disease in September 2018 as demonstrated by MRI and PET/CT ([figure 1A](#F1){ref-type="fig"}). The expression of GD~2~ was confirmed in September 2018 after obtaining tumor tissue to explore further therapeutic options.

![PET/CT in patient 1. The black and white arrows indicate the most prominent soft tissue metastases in the pelvic and inguinal region. (A) September 2018, prior to therapy with DB and nivolumab. (B) January 2019, pseudoprogression with a more intense PET signal. (C) May 2019. (D) October 2019. (E) March 2020. In C, D and E there is no evidence of the former soft tissue metastases. PET/CT, positron emission tomography/computed tomography.](jitc-2020-000540f01){#F1}

###### 

Key details of the patients' diagnosis and treatment

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Date                              Disease stage                                                                Treatment
  --------------------------------- ---------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **4-Year old girl**                                                                                            

  August 2013 to 2015\              Diagnosis of retroperitoneal NB, stage 4 (INSS), *MYCN* amplifiedFirst CR    Chemotherapy according to HR-NBL1/SIOPEN (rapid COJEC, TVD)HD chemotherapy with busulfan/melphalan and ASCTTwo tumor resections in May 2014 and July 2014Local radiotherapy to the lumbar regionImmunotherapy with dinutuximab beta and IL-2
  (home country)                                                                                                 

  January 2017 to November 2017\    First relapse, localized advancedPR                                          Tumor resectionChemotherapy according to the RIST trial, partly with bevacizumabSecond HD chemotherapy with thiotepa/cyclophosphamide and ASCTSecond radiotherapy
  (home country)                                                                                                 

  December 2017 to September 2018   PRPR followed by PD                                                          Immunotherapy with dinutuximab beta in combination with chemotherapy courses from trial NB2004 (N5, N6)Immunotherapy with dinutuximab beta in combination with irinotecan/temozolomide

  October 2018 to August 2019       PDSecond CR in May 2019                                                      Immunotherapy with dinutuximab beta and nivolumab

  August 2019 to March 2020         Persistent second complete remission (CR)                                    None

  **17-Year-old young man**                                                                                      

  April 2010 to July 2010           Diagnosis of left adrenal NB, stage 2 (INSS), *MYCN* non-amplifiedFirst CR   Tumor surgeryChemotherapy according to trial NB2004 (2x N5, 2x N6, composition see above)

  July 2011 to July 2012            First relapse, localPD in July 2012                                          Chemotherapy according to the RIST trial (composition see above)Tumor resection, one course of postsurgical cyclophosphamideImmunotherapy with dinutuximab beta and IL-2

  July 2012--October 2012           PDSecond CR                                                                  Chemotherapy according to trial NB2004 (2x N8)Tumor resection

  February 2014--July 2014          Second relapse, localThird complete remission                                Tumor resectionRadiotherapySystemic therapy declined

  June 2018 to May 2019             Third relapse, metastaticPR followed by PD                                   Chemotherapy according to trial NB2004 (N5/N6 courses)Tumor resection (nephrectomy and adrenalectomy left)Local radiotherapymIBG-therapy

  June 2019 to ongoing              PDPR                                                                         Immunotherapy with DB and nivolumab
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ASCT, autologous stem cell transplantation; CR, complete remission; DB, dinutuximab beta; HD, high dose; IL-2, interleukin 2; INSS, International Neuroblastoma Staging System; mIBG, metaiodobenzylguanidine; N5, cisplatin, etoposide, vindesine; N6, vincristine, dacarbacine, ifosfamide, doxorubicin; N8, topotecan, cyclophosphamide, etoposide; NB, neuroblastoma; NB2004, neuroblastoma 2004 protocol (Germany); PD, progressive disease; PR, partial remission; Rapid COJEC, carboplatin, etoposide, cisplatin, cyclophosphamide; RIST, sirolimus, irinotecan, dasatinib, temozolomide; TVD, topotecan, vincristine, doxorubicin.

Considering the reduced tolerance to her relapse treatment, but her still good quality of life, we decided to apply a combined immunotherapy using nivolumab and DB. From October 2018 until August 2019, the girl received 19 doses of nivolumab (3 mg/kg body weight (BW) every 2 weeks) and 8 courses of DB (100 mg/m² body surface area in 10 days, every 6 weeks). In January 2019, progressive disease was suspected in routine MRI and PET/CT scans ([figure 1B](#F1){ref-type="fig"}). Nevertheless, we decided to continue treatment, as the general condition of the girl was excellent. Interestingly, PET/CT scans in May 2019 ([figure 1C](#F1){ref-type="fig"}), August 2019, November 2019 ([figure 1D](#F1){ref-type="fig"}) and March 2020 ([figure 1E](#F1){ref-type="fig"}) showed a complete resolution of the disease with no residual tumors in the retroperitoneal and inguinal region. This was confirmed by MRI scans. We decided to stop immunotherapy 3 months after the patient achieved the second complete remission. Autoimmune phenomena were not observed during or after immunotherapy. The girl did not receive any blood products from October 2018 until March 2020. Apart from a single urinary tract infection in December 2018, tolerance to treatment was excellent. She is disease-free, at home with her parents, visits school and is fully active.

Patient 2 {#s2-2}
---------

The 17-year-old young man was diagnosed in April 2010 with *MYCN* non-amplified NB, INSS stage L, originating from the left adrenal gland. After two local relapses, his disease progressed to stage M in June 2018 with multiple bone metastases and a large abdominal mass at the site of the primary tumor. The first-line and relapse treatments followed a high-intensity multimodal approach ([table 1](#T1){ref-type="table"}). Treatment from June 2018 until May 2019 included chemotherapy according to the high-risk group in neuroblastoma 2004 protocol (Germany), resection of the large abdominal mass with left-sided nephrectomy and local radiotherapy. We intended to proceed to mIBG therapy followed by high-dose chemotherapy and autologous stem cell rescue. However, the therapeutic mIBG scan from May 2019 revealed a considerable increase of bone metastases. As high-dose chemotherapy is not an option in progressive disease, this concept of treatment was abandoned. Detailed analysis of the tumor tissue after resection in January 2019 had confirmed the expression of GD~2~ and PD-L1.

Despite progressive disease, the patient still had a good quality of life without continuous pain or relevant disabilities. Based on the experience with patient 1 and the exploitation of all conventional therapeutic options, we applied DB and nivolumab. From June 2019 until February 2020, the patient received 19 doses of nivolumab (3 mg/kg BW, every 2 weeks) and 7 courses of DB (100 mg/m² in 10 days, every 6 weeks). In February 2020, we found a substantial regression of skeletal lesions in mIBG scans ([figure 2A, B](#F2){ref-type="fig"}). He is still receiving treatment. The young man had one febrile episode caused by an infection of the central venous line. We did not observe any autoimmune phenomena. He did not receive any blood products from June 2019 until February 2020. His quality of life is excellent. He married in August 2019, is fully active and plans to resume his academic career.

![mIBG in patient 2. The black arrows indicate the most prominent skeletal and soft tissue metastases in the pelvic bone, in the skull and in the para-aortal region (level of the 12th thoracic vertebral body). (A) May 2019, prior to therapy with DB and nivolumab. (B) March 2020, substantial regression of the skeletal metastases and resolution of the soft tissue metastases. DB, dinutuximab beta; mIGB, metaiodobenzylguanidine.](jitc-2020-000540f02){#F2}

In both patients, tumor markers as catecholamine metabolites in the urine and neuron-specific enolase were checked several times during treatment. However, we did not find any consistent association with the results of the imaging studies.

Discussion {#s3}
==========

First-line treatment for patients with high-risk NB involves a multimodal approach combining chemotherapy, surgery, high-dose chemotherapy with autologous stem cell rescue with or without mIBG therapy and external beam radiotherapy. In addition, maintenance therapy with DB is standard of care in high-risk NB.[@R15]

Patients with refractory disease or multiple relapses of NB have a dismal prognosis when standard treatment approaches have failed.[@R16] Immune therapy with DB either alone or in combination with a haploidentical stem cell transplant procedure is an option currently explored for individual patients.[@R17]

In the past decade, checkpoint inhibitors have gained particular interest in various malignant diseases of adult patients including melanoma, non-small cell lung cancer and Hodgkin lymphoma.[@R18] Since 2011, seven checkpoint inhibitors have been approved including nivolumab. Based on the observation that DB leads to an upregulation of the PD-1/PD-L1 checkpoint[@R14] in a preclinical model with a synergistic therapeutic effect when combined with an anti-PD-1 antibody, we applied this combination in two heavily pretreated patients with relapsed/refractory NB. The outcome was very promising as both patients showed an excellent response to this treatment. In patient 1, progressive disease was suspected at staging examinations after 3 months of therapy. It is well known, that checkpoint inhibitors may result in pseudoprogression after the first few weeks of treatment due to immunotherapy-induced inflammatory reaction.[@R21] Considering pseudoprogression and the excellent general condition of the patient, we decided to continue her treatment as planned. Four months later, all PET-positive lesions had disappeared. The complete response was confirmed by MRI scans. The CR was stable as further PET/CTs at the end of therapy and in the patient's 3-month and 6-month follow-up revealed no evidence of disease. In patient 2, the response to treatment was documented by MRI and mIBG scans. Regression of tumor tissue was clearly seen in the patient's soft tissue lesions and in the bone metastases. As both patients had previous, unsuccessful therapies with DB alone or in combination with IL-2 or chemotherapy, we consider the addition of immune therapy with nivolumab as the decisive element for the favorable outcome documented in our two patients.

Conclusions {#s4}
===========

We report the first results of a combined treatment with nivolumab and DB in two patients with relapsed/refractory NB. The response to treatment was excellent. The first patient is now 6 months after end of therapy in ongoing complete remission. The second patient has reached a partial remission and is still receiving treatment. Treatment-related toxicities were mild and well manageable; in particular, we did not observe any autoimmune phenomena. Both patients have an excellent quality of life and are fully active. These results suggest that combined immune therapy with nivolumab and DB may be a promising strategy to be explored in a prospective clinical trial.
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